CrownCast

🎥Crown Bioscience
  • 0.0 (0)
  • LIFE SCIENCES

CrownCast, Crown Bioscience's podcast aims to discuss the emerging trends, breakthroughs, and viewpoints in oncology drug discovery, and development.

  1. ADC Development Revolution - Leveraging Translational Models for Next-Generation Cancer Therapeutics

    1D AGO · VIDEO

    ADC Development Revolution - Leveraging Translational Models for Next-Generation Cancer Therapeutics

    CrownCast

    25 min
  2. CrownCast - The Radiopharmaceutical Revolution Driving Precision in Treatment

    JAN 8 · VIDEO

    CrownCast - The Radiopharmaceutical Revolution Driving Precision in Treatment

    CrownCast

    26 min
  3. Transforming Cancer Drug Development in the UK: Perspectives and Breakthroughs

    11/11/2025 · VIDEO

    Transforming Cancer Drug Development in the UK: Perspectives and Breakthroughs

    Across the global oncology drug discovery landscape, the UK stands at the forefront. In this CrownCast episode, Rajendra Kumari, Executive Director of Integrated Solutions at Crown Bioscience, talks with Sarah Wagner, Senior Director of Business Development and Bryan Miller, Director of Scientific and Technical Operations about leveraging the UK’s vibrant ecosystem of cutting-edge technologies, strong collaborations, and a commitment to high ethical standards.

    25 min
  4. Harnessing the Power of High-quality Biospecimens

    10/30/2025 · VIDEO

    Harnessing the Power of High-quality Biospecimens

    As cancer research progresses rapidly, obtaining high-quality biospecimens has grown increasingly important for making significant breakthroughs. In this CrownCast episode, Rajendra Kumari, Executive Director of Integrated Solutions at Crown Bioscience, talks with Sadaf Malik, Senior Director, Head US Sales (Biobank and Biomarker) about how superior biospecimens can drive advancements in oncology by means of innovative biobanking.

    26 min
  5. The Future of Drug Development: How Organoids Are Leading the Charge

    08/05/2025 · VIDEO

    The Future of Drug Development: How Organoids Are Leading the Charge

    As the landscape of drug discovery evolves, breakthrough technologies like organoids are gaining traction for their potential to revolutionize how new treatments are developed. In this episode of CrownCast, Jonny McMichael, Vice President at Crown Bioscience, and Leo Price, a member of Crown Bioscience’s Scientific Advisory Board, shed light on organoids' growing role in drug development. With insights into their application, this commentary delves into a technology that offers a significant leap toward personalized medicine, ushering in a new era for the healthcare industry.

    33 min

  6. 06/27/2025 · VIDEO

    Navigating the Future of Preclinical Testing Post-FDA Animal Testing Mandate

    In the relentlessly evolving landscape of drug discovery, modern technologies and groundbreaking methods are going beyond animal testing to ensure a more human-centric, efficient, and improved approach in terms of reliability. It's a journey that promises a more efficient future for pharmaceutical companies and, ultimately, patients worldwide. Dive into the details with industry leader Professor Thomas Hartung, shedding light on how policy changes and innovative technologies are setting the stage for the future. What You'll Learn 00:15 — Cutting-Edge Advances in Non-Animal Testing 07:50 — Regulatory Shifts with the FDA Modernization Act 15:30 — The Role of AI in Drug Discovery 24:10 — Integrating New Approaches into Current Practices Main Points of Conversation: In a time when the complexities of drug development demand rapid, accurate solutions, the adoption of alternative methodologies is crucial. As regulatory bodies worldwide signal a shift away from animal testing, the opportunities for innovative technologies to provide human-relevant data are immense. Executives and decision-makers must understand these transformations to maintain competitive advantages and drive industry standards forward.

    25 min

  7. 05/16/2025 · VIDEO

    Evolving Biomarkers: Charting the Future of Precision Medicine

    In a rapidly shifting landscape of personalized medicine, biomarkers have become central to shaping the way drug development and clinical trials unfold. From predicting therapeutic response to identifying optimal patient populations, the complexity and scope of biomarker use has increased alongside technological advances. A key success story like the BCR-ABL biomarker in chronic myeloid leukemia demonstrates the power of targeted medicine, which has raised five-year survival rates from around 30–50% to over 90%. With the rise of multi-omics and AI-driven analytics, the industry is entering a new era of integration, data complexity—and unprecedented possibility. How early should companies start thinking about biomarker strategy to improve outcomes and reduce clinical trial risk? On this episode of Crown BioScience, host Jonny McMichael sits down with Julie Mayer, VP of the Global Biomarker Platform at Crown BioScience, to explore how biomarkers are revolutionizing oncology drug development. From diagnostic tools to regulatory rigor, they discuss where the field is heading, the success stories already reshaping care, and what it takes to stay ahead of the curve. Main Points of Conversation: The earlier biomarker strategies are developed in the pipeline, the better the potential for trial success and regulatory alignment. Technological advances—like multi-omics and liquid biopsy—are enabling earlier, more accurate, and less invasive patient insights. Future biomarker development will depend heavily on AI and bioinformatics to manage large, complex data and translate it into actionable therapies. Julie Mayer is Vice President of the Global Biomarker Platform at Crown BioScience. With over 15 years of experience in molecular strategy and assay development, she previously held leadership roles at NeoGenomics Laboratories, GenOptix, and Navigate Biopharmaceuticals. Julie holds a PhD in Pathology from the Keck School of Medicine at the University of Southern California.

    24 min
  8. Pioneering Strategies to Unlocking the Potential of KRAS

    05/06/2025 · VIDEO

    Pioneering Strategies to Unlocking the Potential of KRAS

    Once labeled “undruggable,” KRAS has emerged as one of oncology’s most promising—yet complex—targets. With nearly 90% of pancreatic cancers and 30-40% of lung and colorectal cancers harboring KRAS mutations, the need for effective therapies is urgent. Recent FDA approvals of KRAS G12C inhibitors have signaled a new era, but the rise of resistance and diverse mutation profiles demand deeper innovation. As preclinical tools and combination strategies evolve, scientists must ask: how do we stay ahead of KRAS-driven resistance and translate insights into patient-specific treatment success? So, what will it take to overcome the final barriers to fully unlocking the therapeutic potential of KRAS? In this episode of Crowncast, host Jonny McMichael, VP of Client Experience & Enablement at Crown BioScience, is joined by Dr. Rajendra "Jen" Kumari, Executive Director of Integrated Solutions. Together, they delve into KRAS biology, resistance mechanisms, and preclinical strategies reshaping drug discovery. Their conversation touches on cutting-edge translational modeling and what the future holds for combination therapies targeting KRAS mutations. Key topics covered in this episode: Why KRAS mutations are uniquely challenging—and how recent breakthroughs have shifted the “undruggable” narrative. The rise of G12C inhibitors and how resistance is reshaping combination strategies in colorectal and lung cancer. The essential role of preclinical models, including engineered systems and PDXs, in predicting clinical response and guiding next-gen drug development. About the Guest: Dr. Rajendra Kumari brings over two decades of oncology research experience to Crown BioScience. A PhD in pharmacology from the University of Leicester, Jen co-founded preclinical CRO PreCOS in 2010, which was acquired by Crown in 2013. She has held various leadership roles including CSO, COO, and GM of Crown UK, and now leads global integrated solutions, driving innovation in translational modeling and oncology strategy.

    42 min
See All (13)

About

CrownCast, Crown Bioscience's podcast aims to discuss the emerging trends, breakthroughs, and viewpoints in oncology drug discovery, and development.

Information

  • Creator
    🎥Crown Bioscience
  • Years Active
    2025 - 2026
  • Episodes
    13
  • Rating
    Clean
  • Copyright
    © 2025
  • Show Website
    CrownCast